What Y-mAbs Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Hamill Laura | Director | Sep 16 | Disposition to Issuer · D | −25,080 | — | — | 0 |
| Hamill Laura | Director | Sep 16 | Tender Offer · U | −5,825 | $8.60 | −$50.1K | 0 |
| Gill David N | Director | Sep 16 | Disposition to Issuer · D | −25,080 | — | — | 0 |
| Gill David N | Director | Sep 16 | Disposition to Issuer · D | −5,825 | $8.60 | −$50.1K | 0 |
| Healy James | Director | Sep 16 | Tender Offer · U | −2,194,278 | $8.60 | −$18.9M | 0 |
| Healy James | Director | Sep 16 | Disposition to Issuer · D | −25,080 | — | — | 0 |
| Healy James | Director | Sep 16 | Tender Offer · U | −31,603 | $8.60 | −$272K | 0 |
| Pfreundschuh Peter P. | EVP, CFO and Treasurer | Sep 16 | Disposition to Issuer · D | −77,800 | — | — | 0 |
| LaRocca John | SVP, General Counsel & Secry | Sep 16 | Disposition to Issuer · D | −21,500 | — | — | 0 |
| Tyagi Ashu | Director | Sep 16 | Disposition to Issuer · D | −25,080 | — | — | 0 |
| Tyagi Ashu | Director | Sep 16 | Tender Offer · U | −5,825 | $8.60 | −$50.1K | 0 |
| Wedell-Wedellsborg Johan | Director | Sep 16 | Tender Offer · U | −4,559,233 | $8.60 | −$39.2M | 0 |
| Wedell-Wedellsborg Johan | Director | Sep 16 | Disposition to Issuer · D | −25,080 | — | — | 0 |
| Wedell-Wedellsborg Johan | Director | Sep 16 | Tender Offer · U | −5,825 | $8.60 | −$50.1K | 0 |
| Wg Biotech ApS | Director | Sep 16 | Tender Offer · U | −4,559,233 | $8.60 | −$39.2M | 0 |
| Gad Thomas | CHIEF BUSINESS OFFICER | Sep 16 | Tender Offer · U | −60,000 | $8.60 | −$516K | 0 |
| Gad Thomas | CHIEF BUSINESS OFFICER | Sep 16 | Tender Offer · U | −67,681 | $8.60 | −$582K | 0 |
| Gad Thomas | CHIEF BUSINESS OFFICER | Sep 16 | Disposition to Issuer · D | −60,235 | — | — | 0 |
| Gad Thomas | CHIEF BUSINESS OFFICER | Sep 16 | Tender Offer · U | −245,486 | $8.60 | −$2.11M | 0 |
| Wilms Joris | SVP & CHIEF OPERATING OFFICER | Sep 16 | Disposition to Issuer · D | −39,301 | — | — | 0 |
Loading...
